IL15 and neoplasm: The DCs/lysate/IL-15 + cucurbitacin I group: increased survival time of animals (51 days); survival time in the control group was 22 days; complete healing was not achieved. The DCs/lysate/IL-15 + cucurbitacin I + IL-15 group: increased animal survival rate, 70% of animals were alive by day 60, total tumor elimination and healing. Accumulation of CD4+ and CD8+ T cells in metastases